Katelynn M Wilton1, Sara J Achenbach2, John M Davis3, Elena Myasoedova4, Eric L Matteson4, Cynthia S Crowson5. 1. K.M. Wilton, BS, Medical Scientist Training Program, Mayo Clinic College of Medicine and Science. 2. S.J. Achenbach, MS, Division of Biomedical Statistics and Informatics, Mayo Clinic College of Medicine and Science. 3. J.M. Davis III, MD, MS, Division of Rheumatology, Mayo Clinic College of Medicine and Science. 4. E. Myasoedova, MD, PhD, E.L. Matteson, MD, Division of Rheumatology, and Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic College of Medicine and Science. 5. C.S. Crowson, PhD, Division of Biomedical Statistics and Informatics, and Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA. Crowson@mayo.edu.
Abstract
OBJECTIVE: Both erectile dysfunction (ED) and rheumatoid arthritis (RA) are associated with increased cardiovascular (CV) risk. It is unknown if these diagnoses are associated or if their combination confers additional CV risk. We aimed to define the incidence of ED in RA, and to determine if ED correlates with increased CV risk in RA. METHODS: Medical information concerning RA, ED, and CV diagnoses for men with RA (n = 260) diagnosed in Olmsted County, Minnesota, and age-matched male comparators was extracted from a comprehensive medical record system. RESULTS: ED incidence was similar between the RA cohort and comparators (HR 0.80, 95% CI 0.55-1.16). In men with RA, ED diagnosis was associated with a trend toward an increase in peripheral arterial disease (HR 2.22, 95% CI 0.98-5.03) and a significantly decreased rate of myocardial infarction (HR 0.26, 95% CI 0.07-0.90), heart failure (HR 0.49, 95% CI 0.25-0.94), and death (HR 0.56; 95% CI 0.36-0.87). In men with RA and ED, phosphodiesterase-5 inhibitor use was associated with a decreased risk of death (HR 0.35, 95% CI 0.16-0.79), with a trending decreased risk of some CV diagnoses. CONCLUSION: Incidence of ED was not statistically increased in RA. Although patients with both RA and ED had a similar overall CV risk to those with RA alone, men with both RA and ED had decreased risk of heart failure, myocardial infarction, and death, as well as an increased risk of peripheral arterial disease. Further studies are needed to clarify these associations and their implications for pathogenesis and therapeutics.
OBJECTIVE: Both erectile dysfunction (ED) and rheumatoid arthritis (RA) are associated with increased cardiovascular (CV) risk. It is unknown if these diagnoses are associated or if their combination confers additional CV risk. We aimed to define the incidence of ED in RA, and to determine if ED correlates with increased CV risk in RA. METHODS: Medical information concerning RA, ED, and CV diagnoses for men with RA (n = 260) diagnosed in Olmsted County, Minnesota, and age-matched male comparators was extracted from a comprehensive medical record system. RESULTS: ED incidence was similar between the RA cohort and comparators (HR 0.80, 95% CI 0.55-1.16). In men with RA, ED diagnosis was associated with a trend toward an increase in peripheral arterial disease (HR 2.22, 95% CI 0.98-5.03) and a significantly decreased rate of myocardial infarction (HR 0.26, 95% CI 0.07-0.90), heart failure (HR 0.49, 95% CI 0.25-0.94), and death (HR 0.56; 95% CI 0.36-0.87). In men with RA and ED, phosphodiesterase-5 inhibitor use was associated with a decreased risk of death (HR 0.35, 95% CI 0.16-0.79), with a trending decreased risk of some CV diagnoses. CONCLUSION: Incidence of ED was not statistically increased in RA. Although patients with both RA and ED had a similar overall CV risk to those with RA alone, men with both RA and ED had decreased risk of heart failure, myocardial infarction, and death, as well as an increased risk of peripheral arterial disease. Further studies are needed to clarify these associations and their implications for pathogenesis and therapeutics.
Authors: D H Solomon; N J Goodson; J N Katz; M E Weinblatt; J Avorn; S Setoguchi; C Canning; S Schneeweiss Journal: Ann Rheum Dis Date: 2006-06-22 Impact factor: 19.103
Authors: M Heslinga; Iam Van Den Oever; D L Jonker; E N Griep; Hrm Griep-Wentink; Y M Smulders; W F Lems; M Boers; A E Voskuyl; Mjl Peters; D Van Schaardenburg; M T Nurmohamed Journal: Scand J Rheumatol Date: 2019-06-18 Impact factor: 3.641
Authors: Francesco Montorsi; Alberto Briganti; Andrea Salonia; Patrizio Rigatti; Alberto Margonato; Andrea Macchi; Stefano Galli; Paolo M Ravagnani; Piero Montorsi Journal: Eur Urol Date: 2003-09 Impact factor: 20.096
Authors: Cynthia S Crowson; Tina M Gunderson; Hayley J Dykhoff; Elena Myasoedova; Elizabeth J Atkinson; Vanessa L Kronzer; Caitrin M Coffey; John M Davis Iii Journal: RMD Open Date: 2022-01